Safety and Efficacy of Edoxaban in Thoracoscopic Ablation

• Status: Completed
• Trial end date: 2020-07-10
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to compare the safety and efficacy of edoxaban and warfarin for prevention of stroke during a 6-month follow up after total thoracoscopic ablation.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Samsung Medical Center
• Treatments: Edoxaban; Warfarin

Criteria

Inclusion Criteria:

1. Patients aged 18 years or older (not exceed 80 years old).

2. Elective thoracoscopic ablation.

3. Presence of atrial fibrillation (paroxysmal, persistent, long-standing persistent).

Exclusion Criteria:

1. Chronic obstructive pulmonary disease (COPD).

2. History of pulmonary tuberculosis.

3. Other cardiac comorbidities including valvular disease, coronary artery disease.

4. Congenital heart anomalies except for atrial septal defect.

5. Known, clinically important anemia or thrombocytopenia.

6. Pregnancy or lactation.

7. Malignancy.

8. Intracardiac mass or thrombus

9. Life expectancy less than 1 year.